
Surmodics SRDX
Quarterly report 2025-Q2
added 08-08-2025
Surmodics Cash and Cash Equivalents 2011-2026 | SRDX
Annual Cash and Cash Equivalents Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.1 M | 41.4 M | 19 M | 31.2 M | 30.8 M | 30.4 M | 23.3 M | 16.5 M | 25 M | 55.6 M | 43.5 M | 15.5 M | 15.5 M | 23.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.6 M | 15.5 M | 29.1 M |
Quarterly Cash and Cash Equivalents Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.3 M | 29.2 M | 30.1 M | 36.1 M | 24.3 M | 33 M | 23.4 M | 41.4 M | 44.6 M | 19.2 M | 26.4 M | 19 M | - | 24.7 M | 26.6 M | 31.2 M | 62.2 M | 31.2 M | 35.8 M | 30.8 M | 30.8 M | 30.8 M | 9.01 M | 30.4 M | 30.4 M | 30.4 M | 14.4 M | 23.3 M | 23.3 M | 23.3 M | 21.6 M | 16.5 M | 16.5 M | 16.5 M | 17.7 M | 25 M | 25 M | 25 M | 42.7 M | 55.6 M | 55.6 M | 42.7 M | 26.6 M | 43.5 M | 43.5 M | 26.6 M | 10.5 M | 15.5 M | 15.5 M | 10.5 M | 21.5 M | 15.5 M | 15.5 M | 21.5 M | 49.4 M | 23.2 M | 23.2 M | 49.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62.2 M | 9.01 M | 28.3 M |
Cash and Cash Equivalents of other stocks in the Diagnostics research industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
59.4 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.9 B | $ 16.65 | - | $ 179 M | ||
|
Centogene N.V.
CNTG
|
19.1 M | - | -6.23 % | $ 30.6 M | ||
|
Castle Biosciences
CSTL
|
120 M | $ 23.93 | -3.12 % | $ 665 M | ||
|
Agilent Technologies
A
|
1.48 B | $ 113.27 | -1.39 % | $ 34.4 B | ||
|
Accelerate Diagnostics
AXDX
|
34.9 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
1.76 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
12.9 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
18.2 M | - | 0.22 % | $ 16.8 M | ||
|
Neogen Corporation
NEOG
|
129 M | $ 9.11 | -2.52 % | $ 1.98 B | ||
|
Check-Cap Ltd.
CHEK
|
7.7 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
11.9 M | $ 1.59 | -2.72 % | $ 2.12 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.79 B | $ 25.48 | -6.05 % | $ 20 B | ||
|
Personalis
PSNL
|
91.4 M | $ 5.26 | -4.36 % | $ 312 M | ||
|
CareDx, Inc
CDNA
|
65.4 M | $ 19.91 | -9.15 % | $ 1.06 B | ||
|
DermTech
DMTK
|
36.7 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
52.4 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
956 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
55.1 M | $ 14.9 | -2.61 % | $ 451 M | ||
|
Illumina
ILMN
|
1.13 B | $ 124.12 | -2.21 % | $ 19.7 B | ||
|
Global Cord Blood Corporation
CO
|
6.66 B | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
11.7 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
176 M | - | 0.12 % | $ 80.1 M | ||
|
Trinity Biotech plc
TRIB
|
5.17 M | $ 0.61 | -1.21 % | $ 61.9 M | ||
|
Charles River Laboratories International
CRL
|
214 M | $ 168.25 | 0.88 % | $ 8.34 B | ||
|
Twist Bioscience Corporation
TWST
|
183 M | $ 57.54 | -2.72 % | $ 3.44 B | ||
|
HTG Molecular Diagnostics
HTGM
|
12.2 M | - | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
378 M | $ 82.57 | -0.66 % | $ 10.4 B | ||
|
Lantheus Holdings
LNTH
|
359 M | $ 80.89 | -3.18 % | $ 5.46 B | ||
|
Heska Corporation
HSKA
|
157 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
2.5 M | $ 1.96 | 1.5 % | $ 8.67 M | ||
|
Senseonics Holdings
SENS
|
40.2 M | $ 6.86 | -4.44 % | $ 286 M | ||
|
QIAGEN N.V.
QGEN
|
598 M | - | - | $ 10.6 B | ||
|
Medpace Holdings
MEDP
|
497 M | $ 410.67 | 0.22 % | $ 11.8 B | ||
|
Biomerica
BMRA
|
2.4 M | $ 2.16 | -1.47 % | $ 4.96 M | ||
|
Motus GI Holdings
MOTS
|
4.96 M | - | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
752 M | $ 114.53 | 11.74 % | $ 9.45 B | ||
|
Laboratory Corporation of America Holdings
LH
|
532 M | $ 255.97 | -1.39 % | $ 21.3 B | ||
|
NeoGenomics
NEO
|
160 M | $ 9.18 | 1.72 % | $ 1.18 B | ||
|
Celcuity
CELC
|
166 M | $ 119.79 | -0.24 % | $ 5.6 B | ||
|
National Research Corporation
NRC
|
4.14 M | $ 15.0 | -10.93 % | $ 336 M | ||
|
Myriad Genetics
MYGN
|
150 M | $ 4.75 | -1.96 % | $ 440 M | ||
|
Natera
NTRA
|
466 M | $ 194.2 | -2.98 % | $ 19.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
420 M | $ 188.26 | -3.48 % | $ 20.9 B | ||
|
Invitae Corporation
NVTA
|
257 M | - | - | $ 21.2 M | ||
|
Exagen
XGN
|
32.2 M | $ 2.73 | - | $ 58.9 M | ||
|
OpGen
OPGN
|
1.31 M | - | -16.95 % | $ 1.54 M |